145 related articles for article (PubMed ID: 15328124)
1. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases.
Gonzalez LM; Brindeiro RM; Aguiar RS; Pereira HS; Abreu CM; Soares MA; Tanuri A
Antimicrob Agents Chemother; 2004 Sep; 48(9):3552-5. PubMed ID: 15328124
[TBL] [Abstract][Full Text] [Related]
2. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
[TBL] [Abstract][Full Text] [Related]
3. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
[TBL] [Abstract][Full Text] [Related]
4. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
[TBL] [Abstract][Full Text] [Related]
5. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
6. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
[TBL] [Abstract][Full Text] [Related]
7. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
8. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.
Resch W; Ziermann R; Parkin N; Gamarnik A; Swanstrom R
J Virol; 2002 Sep; 76(17):8659-66. PubMed ID: 12163585
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
[TBL] [Abstract][Full Text] [Related]
10. Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.
Perrin V; Mammano F
J Virol; 2003 Sep; 77(18):10172-5. PubMed ID: 12941931
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
12. The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
Martinez-Cajas JL; Wainberg MA; Oliveira M; Asahchop EL; Doualla-Bell F; Lisovsky I; Moisi D; Mendelson E; Grossman Z; Brenner BG
J Antimicrob Chemother; 2012 Apr; 67(4):988-94. PubMed ID: 22315096
[TBL] [Abstract][Full Text] [Related]
13. Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.
Toor JS; Sharma A; Kumar R; Gupta P; Garg P; Arora SK
Antiviral Res; 2011 Nov; 92(2):213-8. PubMed ID: 21875619
[TBL] [Abstract][Full Text] [Related]
14. Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment.
Kagan RM; Cheung PK; Huard TK; Lewinski MA
Antiviral Res; 2006 Aug; 71(1):42-52. PubMed ID: 16600392
[TBL] [Abstract][Full Text] [Related]
15. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
[TBL] [Abstract][Full Text] [Related]
16. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
17. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors.
Menzo S; Monachetti A; Balotta C; Corvasce S; Rusconi S; Paolucci S; Baldanti F; Bagnarelli P; Clementi M
AIDS; 2003 Mar; 17(5):663-71. PubMed ID: 12646788
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
Krauchenco S; Martins NH; Sanches M; Polikarpov I
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):638-45. PubMed ID: 18825538
[TBL] [Abstract][Full Text] [Related]
19. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance within the protease inhibitor class.
Race E
Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
